Affiliation:
1. Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, China.
Abstract
No studies have examined the impact of human papillomavirus (HPV)-16 and HPV-18 on survival, inflammation biomarkers, and immune function in early-stage cervical cancer patients undergoing surgery. Patients diagnosed with early-stage cervical cancer were screened for high-risk HPV prior to surgery. The influence of HPV infection on survival, inflammatory markers, and immune function was investigated. Findings revealed that patients in the HPV-18 positive subgroup exhibited poorer disease-free survival (DFS) and elevated levels of interleukin-6 and C-reactive protein, along with decreased CD4+ T cells compared to patients who tested negative for HPV-18. Notably, early-stage cervical cancer patients with HPV-18 infection experienced worse DFS, heightened inflammatory markers, and compromised immune function.
Reference29 articles.
1. Cancer statistics, 2018;R L Siegel;CA Cancer J Clin,2018
2. Mexican Cervical Cancer Screening Study II: acceptability of human papillomavirus self-sampler;L N Arriba;Int J Gynecol Cancer,2010
3. Papillomaviruses in the causation of human cancers - a brief historical account;H zur Hausen;Virology,2009
4. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors;M Arbyn;Cochrane Database Syst Rev,2018
5. High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study;J Lei;PLoS Med,2018